{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:04:11Z","timestamp":1792213451618,"version":"4.4.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.arbres.2024.06.021","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T19:06:33Z","timestamp":1721070393000},"page":"S59-S66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"S2","title":["NRF2 Signaling Pathway in Chemo\/Radio\/Immuno-Therapy Resistance of Lung Cancer: Looking Beyond the Tip of the Iceberg"],"prefix":"10.1016","volume":"60","author":[{"given":"Sri Vidya","family":"Ramisetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapas","family":"Patra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak","family":"Munirathnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothi Venkat","family":"Sainath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durgadevi","family":"Veeraiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhileshwar","family":"Namani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.arbres.2024.06.021_bib0475","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.arbres.2024.06.021_bib0480","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.canlet.2019.09.016","article-title":"\u201cNRF2 addiction\u201d in lung cancer cells and its impact on cancer therapy","volume":"467","author":"Hammad","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/j.arbres.2024.06.021_bib0485","doi-asserted-by":"crossref","first-page":"102726","DOI":"10.1016\/j.redox.2023.102726","article-title":"The KEAP1-NRF2 pathway: targets for therapy and role in cancer","volume":"63","author":"Adinolfi","year":"2023","journal-title":"Redox Biol"},{"issue":"18","key":"10.1016\/j.arbres.2024.06.021_bib0490","doi-asserted-by":"crossref","first-page":"11908","DOI":"10.1073\/pnas.172398899","article-title":"Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants","volume":"99","author":"Dinkova-Kostova","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.arbres.2024.06.021_bib0495","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1128\/MCB.01704-07","article-title":"Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity","volume":"28","author":"Yamamoto","year":"2008","journal-title":"Mol Cell Biol"},{"issue":"7","key":"10.1016\/j.arbres.2024.06.021_bib0500","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1073\/pnas.0307301101","article-title":"Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers","volume":"101","author":"Wakabayashi","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"10.1016\/j.arbres.2024.06.021_bib0505","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1128\/MCB.00753-07","article-title":"Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response","volume":"27","author":"Tong","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"8","key":"10.1016\/j.arbres.2024.06.021_bib0510","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3390\/cells10081879","article-title":"Role of NRF2 in lung cancer","volume":"10","author":"Sanchez-Ortega","year":"2021","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.arbres.2024.06.021_bib0515","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1074\/jbc.M207293200","article-title":"Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome","volume":"278","author":"Nguyen","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.arbres.2024.06.021_bib0520","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.phrs.2018.06.013","article-title":"Canonical and non-canonical mechanisms of Nrf2 activation","volume":"134","author":"Silva-Islas","year":"2018","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.arbres.2024.06.021_bib0525","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccell.2017.09.008","article-title":"iASPP is an antioxidative factor and drives cancer growth and drug resistance by competing with Nrf2 for Keap1 binding","volume":"32","author":"Ge","year":"2017","journal-title":"Cancer Cell"},{"issue":"Pt B","key":"10.1016\/j.arbres.2024.06.021_bib0530","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.freeradbiomed.2015.04.029","article-title":"Structural and functional characterization of Nrf2 degradation by glycogen synthase kinase 3\/beta-TrCP","volume":"88","author":"Cuadrado","year":"2015","journal-title":"Free Radic Biol Med"},{"issue":"10","key":"10.1016\/j.arbres.2024.06.021_bib0535","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1371\/journal.pmed.0030420","article-title":"Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer","volume":"3","author":"Singh","year":"2006","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.arbres.2024.06.021_bib0540","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/carcin\/bgn095","article-title":"Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2","volume":"29","author":"Wang","year":"2008","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.arbres.2024.06.021_bib0545","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/path.2653","article-title":"Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin","volume":"220","author":"Kim","year":"2010","journal-title":"J Pathol"},{"issue":"14","key":"10.1016\/j.arbres.2024.06.021_bib0550","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1158\/1078-0432.CCR-09-3352","article-title":"Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features","volume":"16","author":"Solis","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.arbres.2024.06.021_bib0555","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/0008-5472.CAN-07-5003","article-title":"Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth","volume":"68","author":"Ohta","year":"2008","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.arbres.2024.06.021_bib0560","doi-asserted-by":"crossref","first-page":"710","DOI":"10.4161\/epi.6.6.15773","article-title":"Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer","volume":"6","author":"Muscarella","year":"2011","journal-title":"Epigenetics"},{"issue":"36","key":"10.1016\/j.arbres.2024.06.021_bib0565","doi-asserted-by":"crossref","first-page":"13568","DOI":"10.1073\/pnas.0806268105","article-title":"Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy","volume":"105","author":"Shibata","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.arbres.2024.06.021_bib0570","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3892\/mmr.2012.921","article-title":"Increased NRF2 gene (NFE2L2) copy number correlates with mutations in lung squamous cell carcinomas","volume":"6","author":"Sasaki","year":"2012","journal-title":"Mol Med Rep"},{"issue":"7417","key":"10.1016\/j.arbres.2024.06.021_bib0575","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","year":"2012","journal-title":"Nature"},{"issue":"7511","key":"10.1016\/j.arbres.2024.06.021_bib0580","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.arbres.2024.06.021_bib0585","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1158\/1078-0432.CCR-08-2822","article-title":"Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer","volume":"15","author":"Homma","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.arbres.2024.06.021_bib0590","doi-asserted-by":"crossref","first-page":"7975","DOI":"10.1158\/0008-5472.CAN-08-1401","article-title":"RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy","volume":"68","author":"Singh","year":"2008","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.arbres.2024.06.021_bib0595","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.freeradbiomed.2012.05.041","article-title":"Regulatory role of KEAP1 and NRF2 in PPARgamma expression and chemoresistance in human non-small-cell lung carcinoma cells","volume":"53","author":"Zhan","year":"2012","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.arbres.2024.06.021_bib0600","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12964-020-00568-z","article-title":"Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1\/NRF2 pathway activation","volume":"18","author":"Gong","year":"2020","journal-title":"Cell Commun Signal"},{"issue":"4","key":"10.1016\/j.arbres.2024.06.021_bib0605","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.humpath.2011.05.024","article-title":"Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer","volume":"43","author":"Merikallio","year":"2012","journal-title":"Hum Pathol"},{"issue":"13","key":"10.1016\/j.arbres.2024.06.021_bib0610","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1158\/0008-5472.CAN-12-4499","article-title":"Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis","volume":"73","author":"Satoh","year":"2013","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.arbres.2024.06.021_bib0615","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1158\/0008-5472.CAN-15-1584","article-title":"NRF2 intensifies host defense systems to prevent lung carcinogenesis, but after tumor initiation accelerates malignant cell growth","volume":"76","author":"Satoh","year":"2016","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.arbres.2024.06.021_bib0620","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/mc.22745","article-title":"The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer","volume":"57","author":"Tao","year":"2018","journal-title":"Mol Carcinog"},{"issue":"2","key":"10.1016\/j.arbres.2024.06.021_bib0625","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1440-1843.2009.01703.x","article-title":"Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response","volume":"15","author":"Gupta","year":"2010","journal-title":"Respirology"},{"issue":"11","key":"10.1016\/j.arbres.2024.06.021_bib0630","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1089\/ars.2010.3219","article-title":"Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance","volume":"13","author":"Singh","year":"2010","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"10.1016\/j.arbres.2024.06.021_bib0635","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JTO.0b013e318233d753","article-title":"Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma","volume":"7","author":"Mahaffey","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"39","key":"10.1016\/j.arbres.2024.06.021_bib0640","doi-asserted-by":"crossref","first-page":"41692","DOI":"10.18632\/oncotarget.6150","article-title":"Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2","volume":"6","author":"Tung","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.arbres.2024.06.021_bib0645","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3390\/cells8091105","article-title":"Cellular stress responses in radiotherapy","volume":"8","author":"Kim","year":"2019","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.arbres.2024.06.021_bib0650","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.freeradbiomed.2012.05.038","article-title":"An effective strategy for increasing the radiosensitivity of human lung cancer cells by blocking Nrf2-dependent antioxidant responses","volume":"53","author":"Lee","year":"2012","journal-title":"Free Radic Biol Med"},{"issue":"7","key":"10.1016\/j.arbres.2024.06.021_bib0655","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3390\/ijms17070997","article-title":"Brusatol enhances the radiosensitivity of A549 cells by promoting ROS production and enhancing DNA damage","volume":"17","author":"Sun","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.arbres.2024.06.021_bib0660","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/mc.22609","article-title":"Brusatol overcomes chemoresistance through inhibition of protein translation","volume":"56","author":"Harder","year":"2017","journal-title":"Mol Carcinog"},{"issue":"2","key":"10.1016\/j.arbres.2024.06.021_bib0665","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3892\/ijo.2015.3301","article-title":"Downregulation of Nrf2 promotes radiation-induced apoptosis through Nrf2 mediated Notch signaling in non-small cell lung cancer cells","volume":"48","author":"Zhao","year":"2016","journal-title":"Int J Oncol"},{"issue":"22","key":"10.1016\/j.arbres.2024.06.021_bib0670","doi-asserted-by":"crossref","first-page":"36603","DOI":"10.18632\/oncotarget.16622","article-title":"Suppression of radiation-induced migration of non-small cell lung cancer through inhibition of Nrf2-Notch Axis","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.arbres.2024.06.021_bib0675","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1158\/2159-8290.CD-20-0282","article-title":"KEAP1\/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition","volume":"10","author":"Binkley","year":"2020","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.arbres.2024.06.021_bib0680","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1158\/1078-0432.CCR-20-2859","article-title":"STK11\/LKB1 mutations in NSCLC are associated with KEAP1\/NRF2-dependent radiotherapy resistance targetable by glutaminase inhibition","volume":"27","author":"Sitthideatphaiboon","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.arbres.2024.06.021_bib0685","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.21037\/tlcr-22-292","article-title":"NRF2-pathway mutations predict radioresistance in non-small cell lung cancer","volume":"11","author":"Kinslow","year":"2022","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"10.1016\/j.arbres.2024.06.021_bib0690","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7150\/thno.88899","article-title":"NRF2 promotes radiation resistance by cooperating with TOPBP1 to activate the ATR-CHK1 signaling pathway","volume":"14","author":"Sun","year":"2024","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.arbres.2024.06.021_bib0695","doi-asserted-by":"crossref","first-page":"631","DOI":"10.21037\/tlcr.2018.08.04","article-title":"Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?","volume":"7","author":"Heeke","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.arbres.2024.06.021_bib0700","doi-asserted-by":"crossref","first-page":"1129465","DOI":"10.3389\/fimmu.2023.1129465","article-title":"Immunotherapy resistance in non-small-cell lung cancer: from mechanism to clinical strategies","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.arbres.2024.06.021_bib0705","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmet.2018.02.006","article-title":"Synergy between the KEAP1\/NRF2 and PI3K pathways drives non-small-cell lung cancer with an altered immune microenvironment","volume":"27","author":"Best","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.arbres.2024.06.021_bib0710","doi-asserted-by":"crossref","first-page":"117923","DOI":"10.1016\/j.lfs.2020.117923","article-title":"Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer","volume":"256","author":"Shen","year":"2020","journal-title":"Life Sci"},{"issue":"6","key":"10.1016\/j.arbres.2024.06.021_bib0715","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.jtho.2020.02.027","article-title":"KEAP1-NFE2L2-mutant NSCLC and immune checkpoint inhibitors: a large database analysis","volume":"15","author":"Zhang","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.arbres.2024.06.021_bib0720","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.annonc.2020.08.2105","article-title":"KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden","volume":"31","author":"Marinelli","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.arbres.2024.06.021_bib0725","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"50","key":"10.1016\/j.arbres.2024.06.021_bib0730","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1038\/s41388-021-02054-3","article-title":"Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma","volume":"40","author":"Bischoff","year":"2021","journal-title":"Oncogene"},{"issue":"18","key":"10.1016\/j.arbres.2024.06.021_bib0735","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/1759-7714.14089","article-title":"Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment","volume":"12","author":"Cheng","year":"2021","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.arbres.2024.06.021_bib0740","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2021.12.005","article-title":"EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion","volume":"185","author":"Marzio","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.arbres.2024.06.021_bib0745","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2022.06.010","article-title":"STK11 and KEAP1 mutations in non-small cell lung cancer patients: descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)","volume":"170","author":"Cordeiro de Lima","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.arbres.2024.06.021_bib0750","doi-asserted-by":"crossref","first-page":"102644","DOI":"10.1016\/j.redox.2023.102644","article-title":"A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies","volume":"61","author":"Harkonen","year":"2023","journal-title":"Redox Biol"},{"issue":"11","key":"10.1016\/j.arbres.2024.06.021_bib0755","doi-asserted-by":"crossref","first-page":"113295","DOI":"10.1016\/j.celrep.2023.113295","article-title":"KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance","volume":"42","author":"Zavitsanou","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.arbres.2024.06.021_bib0760","doi-asserted-by":"crossref","first-page":"102904","DOI":"10.1016\/j.redox.2023.102904","article-title":"Immunoediting of KEAP1-NRF2 mutant tumours is required to circumvent NRF2-mediated immune surveillance","volume":"67","author":"Baird","year":"2023","journal-title":"Redox Biol"},{"issue":"1","key":"10.1016\/j.arbres.2024.06.021_bib0765","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2012.05.016","article-title":"Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming","volume":"22","author":"Mitsuishi","year":"2012","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.arbres.2024.06.021_bib0770","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1172\/JCI66353","article-title":"Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis","volume":"123","author":"Singh","year":"2013","journal-title":"J Clin Invest"},{"issue":"24","key":"10.1016\/j.arbres.2024.06.021_bib0775","doi-asserted-by":"crossref","first-page":"12600","DOI":"10.18632\/aging.102590","article-title":"Genome-wide global identification of NRF2 binding sites in A549 non-small cell lung cancer cells by ChIP-Seq reveals NRF2 regulation of genes involved in focal adhesion pathways","volume":"11","author":"Namani","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"10.1016\/j.arbres.2024.06.021_bib0780","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.pharmthera.2013.12.003","article-title":"The role of FAK in tumor metabolism and therapy","volume":"142","author":"Zhang","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.arbres.2024.06.021_bib0785","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/cas.14278","article-title":"Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites","volume":"111","author":"Saigusa","year":"2020","journal-title":"Cancer Sci"},{"issue":"41","key":"10.1016\/j.arbres.2024.06.021_bib0790","doi-asserted-by":"crossref","first-page":"69847","DOI":"10.18632\/oncotarget.19349","article-title":"NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer","volume":"8","author":"Namani","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.arbres.2024.06.021_bib0795","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1038\/s41467-019-12164-y","article-title":"Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma","volume":"10","author":"Best","year":"2019","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.arbres.2024.06.021_bib0800","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.3390\/cancers14102543","article-title":"Mutational activation of the NRF2 pathway upregulates kynureninase resulting in tumor immunosuppression and poor outcome in lung adenocarcinoma","volume":"14","author":"Fahrmann","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.arbres.2024.06.021_bib0805","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bbrc.2011.09.014","article-title":"Enhanced sensitivity of A549 cells to the cytotoxic action of anticancer drugs via suppression of Nrf2 by procyanidins from Cinnamomi Cortex extract","volume":"413","author":"Ohnuma","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"10.1016\/j.arbres.2024.06.021_bib0810","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.freeradbiomed.2011.03.008","article-title":"Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2\/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs","volume":"50","author":"Tang","year":"2011","journal-title":"Free Radic Biol Med"},{"issue":"40","key":"10.1016\/j.arbres.2024.06.021_bib0815","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1038\/onc.2012.493","article-title":"Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity","volume":"32","author":"Arlt","year":"2013","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.arbres.2024.06.021_bib0820","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/ptr.3477","article-title":"Seven quassinoids from Fructus Bruceae with cytotoxic effects on pancreatic adenocarcinoma cell lines","volume":"25","author":"Zhao","year":"2011","journal-title":"Phytother Res"},{"issue":"5","key":"10.1016\/j.arbres.2024.06.021_bib0825","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s12272-009-1503-8","article-title":"A new triterpenoid from Brucea javanica","volume":"32","author":"Liu","year":"2009","journal-title":"Arch Pharm Res"},{"issue":"4","key":"10.1016\/j.arbres.2024.06.021_bib0830","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.vetpar.2008.09.021","article-title":"In vitro antitrypanosomal activities of quassinoid compounds from the fruits of a medicinal plant, Brucea javanica","volume":"158","author":"Bawm","year":"2008","journal-title":"Vet Parasitol"},{"issue":"4","key":"10.1016\/j.arbres.2024.06.021_bib0835","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1073\/pnas.1014275108","article-title":"Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism","volume":"108","author":"Ren","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.arbres.2024.06.021_bib0840","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cbi.2013.08.008","article-title":"Chrysin enhances sensitivity of BEL-7402\/ADM cells to doxorubicin by suppressing PI3K\/Akt\/Nrf2 and ERK\/Nrf2 pathway","volume":"206","author":"Gao","year":"2013","journal-title":"Chem Biol Interact"},{"issue":"5","key":"10.1016\/j.arbres.2024.06.021_bib0845","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.3892\/or.2016.4654","article-title":"Oridonin inhibits the proliferation of human colon cancer cells by upregulating BMP7 to activate p38 MAPK","volume":"35","author":"Ren","year":"2016","journal-title":"Oncol Rep"},{"issue":"4","key":"10.1016\/j.arbres.2024.06.021_bib0850","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3109\/10428194.2015.1061127","article-title":"Reactive oxygen species mediate oridonin-induced apoptosis through DNA damage response and activation of JNK pathway in diffuse large B cell lymphoma","volume":"57","author":"Xu","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.arbres.2024.06.021_bib0855","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1142\/S0192415X13500134","article-title":"Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells","volume":"41","author":"Wang","year":"2013","journal-title":"Am J Chin Med"},{"issue":"1","key":"10.1016\/j.arbres.2024.06.021_bib0860","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41419-017-0031-6","article-title":"Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-gamma and inhibiting Nrf2 pathway","volume":"9","author":"Lu","year":"2018","journal-title":"Cell Death Dis"},{"issue":"11\u201312","key":"10.1016\/j.arbres.2024.06.021_bib0865","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1080\/10715762.2018.1489132","article-title":"Suppression of NRF2\/ARE by convallatoxin sensitises A549 cells to 5-FU-mediated apoptosis","volume":"52","author":"Lee","year":"2018","journal-title":"Free Radic Res"},{"key":"10.1016\/j.arbres.2024.06.021_bib0870","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.freeradbiomed.2016.12.041","article-title":"Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation","volume":"103","author":"Tsuchida","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.arbres.2024.06.021_bib0875","first-page":"5511","article-title":"Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells","volume":"9","author":"Pan","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.arbres.2024.06.021_bib0880","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2018.09.004","article-title":"Triptolide enhances chemotherapeutic efficacy of antitumor drugs in non-small-cell lung cancer cells by inhibiting Nrf2-ARE activity","volume":"358","author":"Zhu","year":"2018","journal-title":"Toxicol Appl Pharmacol"},{"issue":"11","key":"10.1016\/j.arbres.2024.06.021_bib0885","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","article-title":"Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors","volume":"11","author":"Singh","year":"2016","journal-title":"ACS Chem Biol"},{"issue":"9","key":"10.1016\/j.arbres.2024.06.021_bib0890","doi-asserted-by":"crossref","first-page":"113104","DOI":"10.1016\/j.celrep.2023.113104","article-title":"A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants","volume":"42","author":"Aboulkassim","year":"2023","journal-title":"Cell Rep"},{"issue":"13","key":"10.1016\/j.arbres.2024.06.021_bib0895","doi-asserted-by":"crossref","first-page":"eadm9859","DOI":"10.1126\/sciadv.adm9859","article-title":"Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer","volume":"10","author":"Pillai","year":"2024","journal-title":"Sci Adv"},{"issue":"2","key":"10.1016\/j.arbres.2024.06.021_bib0900","doi-asserted-by":"crossref","first-page":"e00473","DOI":"10.1128\/MCB.00473-20","article-title":"NRF2-dependent bioactivation of mitomycin c as a novel strategy to target KEAP1-NRF2 pathway activation in human cancer","volume":"41","author":"Baird","year":"2021","journal-title":"Mol Cell Biol"},{"issue":"22","key":"10.1016\/j.arbres.2024.06.021_bib0905","doi-asserted-by":"crossref","first-page":"e00377","DOI":"10.1128\/MCB.00377-20","article-title":"Geldanamycin-derived HSP90 inhibitors are synthetic lethal with NRF2","volume":"40","author":"Baird","year":"2020","journal-title":"Mol Cell Biol"},{"issue":"11","key":"10.1016\/j.arbres.2024.06.021_bib0910","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1158\/1078-0432.CCR-14-2206","article-title":"NRF2 pathway activation and adjuvant chemotherapy benefit in lung squamous cell carcinoma","volume":"21","author":"Cescon","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arbres.2024.06.021_bib0915","doi-asserted-by":"crossref","first-page":"16889","DOI":"10.1038\/srep16889","article-title":"Nuclear factor, erythroid 2-like 2-associated molecular signature predicts lung cancer survival","volume":"5","author":"Qian","year":"2015","journal-title":"Sci Rep"},{"issue":"27","key":"10.1016\/j.arbres.2024.06.021_bib0920","doi-asserted-by":"crossref","first-page":"6813","DOI":"10.7150\/jca.35489","article-title":"Systematic identification of multi omics-based biomarkers in KEAP1 mutated TCGA lung adenocarcinoma","volume":"10","author":"Namani","year":"2019","journal-title":"J Cancer"},{"issue":"1","key":"10.1016\/j.arbres.2024.06.021_bib0925","doi-asserted-by":"crossref","first-page":"12846","DOI":"10.1038\/s41598-018-31281-0","article-title":"A catalogue of somatic NRF2 gain-of-function mutations in cancer","volume":"8","author":"Kerins","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.arbres.2024.06.021_bib0930","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.redox.2018.07.026","article-title":"A distinct class of antioxidant response elements is consistently activated in tumors with NRF2 mutations","volume":"19","author":"Levings","year":"2018","journal-title":"Redox Biol"},{"issue":"8","key":"10.1016\/j.arbres.2024.06.021_bib0935","doi-asserted-by":"crossref","first-page":"7183","DOI":"10.18632\/aging.103068","article-title":"Integrated data analysis reveals significant associations of KEAP1 mutations with DNA methylation alterations in lung adenocarcinomas","volume":"12","author":"Elshaer","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"12","key":"10.1016\/j.arbres.2024.06.021_bib0940","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/bjc.2016.363","article-title":"Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer","volume":"115","author":"MacLeod","year":"2016","journal-title":"Br J Cancer"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289624002679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289624002679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T15:37:21Z","timestamp":1730389041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289624002679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":94,"alternative-id":["S0300289624002679"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2024.06.021","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NRF2 Signaling Pathway in Chemo\/Radio\/Immuno-Therapy Resistance of Lung Cancer: Looking Beyond the Tip of the Iceberg","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2024.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}